Distinguished in Familial Prostate Cancer

Dr. Channing J. Paller

Oncology
Johns Hopkins University
8600 Old Georgetown Rd, 
Bethesda, MD 
Accepting New Patients
Offers Telehealth
Distinguished in Familial Prostate Cancer
Johns Hopkins University
8600 Old Georgetown Rd, 
Bethesda, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Channing Paller is an Oncologist in Bethesda, Maryland. Dr. Paller is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. Her top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, Hormone Replacement Therapy (HRT), and Prostatectomy. Dr. Paller is currently accepting new patients.

Her clinical research consists of co-authoring 131 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles and participated in 1 clinical trial in the study of Familial Prostate Cancer.

Specialties
Oncology
Licenses
Internal Medicine in MD
Hospital Affiliations
Sibley Memorial Hospital
The Johns Hopkins Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

JOHNS HOPKINS UNIVERSITY
8600 Old Georgetown Rd, Bethesda, MD 20814
Other Locations
JOHNS HOPKINS UNIVERSITY
5255 Loughboro Rd Nw, Sibley Memorial Hospital, Washington, DC 20016

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone
Study Phase: Phase 2
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: July 31, 2025
Intervention Type: Biological
Study Drugs: MGC018, MGA012
Study Phase: Phase 1/Phase 2
Overcoming Drug Resistance in Metastatic Castration-resistant Prostate Cancer With Novel Combination of TGF-β Receptor Inhibitor LY2157299 and Enzalutamide: a Randomized Multi-site Phase II Study
Overcoming Drug Resistance in Metastatic Castration-resistant Prostate Cancer With Novel Combination of TGF-β Receptor Inhibitor LY2157299 and Enzalutamide: a Randomized Multi-site Phase II Study
Enrollment Status: Active_not_recruiting
Publish Date: June 06, 2025
Intervention Type: Drug
Study Drugs: Enzalutamide, LY2157299
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2024
Intervention Type: Drug
Study Drug: Fuzuloparib+Abiraterone Acetate+Prednisone
Study Phase: Phase 3
A Phase II Randomized Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS)
A Phase II Randomized Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS)
Enrollment Status: Active_not_recruiting
Publish Date: November 04, 2024
Intervention Type: Drug, Radiation
Study Drug: Radium-223
Study Phase: Phase 2
CYCLONE 1: A Phase 2 Study of Abemaciclib in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With a Novel Hormonal Agent and Taxane-based Chemotherapy
CYCLONE 1: A Phase 2 Study of Abemaciclib in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With a Novel Hormonal Agent and Taxane-based Chemotherapy
Enrollment Status: Completed
Publish Date: June 25, 2024
Intervention Type: Drug
Study Drug: Abemaciclib
Study Phase: Phase 2
A Randomized Phase 2 Trial of Ascorbic Acid in Combination With Docetaxel in Men With Metastatic Prostate Cancer
A Randomized Phase 2 Trial of Ascorbic Acid in Combination With Docetaxel in Men With Metastatic Prostate Cancer
Enrollment Status: Terminated
Publish Date: June 07, 2023
Intervention Type: Other, Dietary supplement, Drug
Study Drug: Docetaxel
Study Phase: Phase 2
A Randomized Double-Blind, Placebo-Controlled Study Of The Effects Of MPX Capsules On Rising Prostate-Specific Antigen Levels In Alanine/Alanine SOD2 Genotype Men Following Initial Therapy For Prostate Cancer
A Randomized Double-Blind, Placebo-Controlled Study Of The Effects Of MPX Capsules On Rising Prostate-Specific Antigen Levels In Alanine/Alanine SOD2 Genotype Men Following Initial Therapy For Prostate Cancer
Enrollment Status: Terminated
Publish Date: May 22, 2023
Intervention Type: Drug
Study Drug: Muscadine Plus
Study Phase: Phase 3
A Phase I Dose Escalating Trial of Mistletoe Extract in Patients With Advanced Solid Tumors
A Phase I Dose Escalating Trial of Mistletoe Extract in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: December 08, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) Followed by Enzalutamide or Abiraterone Post-BAT in Men With Prostate Cancer Progressing on Combined Androgen Ablative Therapies
A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) Followed by Enzalutamide or Abiraterone Post-BAT in Men With Prostate Cancer Progressing on Combined Androgen Ablative Therapies
Enrollment Status: Completed
Publish Date: June 27, 2022
Intervention Type: Drug
Study Drugs: Testosterone cypionate, Testosterone enanthate, Abiraterone acetate, Enzalutamide
Study Phase: Phase 2
A Phase 2 Study of Sipuleucel-T With or Without Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-Metastatic Castrate-Resistant Prostate Cancer
A Phase 2 Study of Sipuleucel-T With or Without Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-Metastatic Castrate-Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: July 08, 2021
Intervention Type: Biological, Drug
Study Drugs: Radium-223, Sipuleucel-T
Study Phase: Phase 2
A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: March 09, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 12 Less Clinical Trials

131 Total Publications

Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS Registry.
Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS Registry.
Journal: JCO precision oncology
Published: September 19, 2025
Similar Doctors
Elite in Familial Prostate Cancer
Dr. Michael A. Carducci
Oncology
Elite in Familial Prostate Cancer
Dr. Michael A. Carducci
Oncology

Johns Hopkins University

600 N Wolf St, 
Baltimore, MD 
 (34.6 miles away)
410-955-5000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Carducci is an Oncologist in Baltimore, Maryland. Dr. Carducci is rated as an Elite provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Prostate Cancer, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Orchiectomy.

Distinguished in Familial Prostate Cancer
Dr. Nancy A. Dawson
Oncology | Hematology Oncology | Hematology
Distinguished in Familial Prostate Cancer
Dr. Nancy A. Dawson
Oncology | Hematology Oncology | Hematology

Medstar Medical Group Ii LLC

3800 Reservoir Rd Nw, 
Washington, DC 
 (6.2 miles away)
202-444-2000
Experience:
46+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nancy Dawson is an Oncologist and a Hematologist Oncology provider in Washington, Washington, D.c.. Dr. Dawson has been practicing medicine for over 46 years and is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. Her top areas of expertise are Prostate Cancer, Familial Prostate Cancer, WT1-Related Wilms Tumor Syndromes, and Chromophobe Renal Cell Carcinoma. Dr. Dawson is currently accepting new patients.

Distinguished in Familial Prostate Cancer
Dr. Mario A. Eisenberger
Oncology
Distinguished in Familial Prostate Cancer
Dr. Mario A. Eisenberger
Oncology
600 N Wolfe St, 
Baltimore, MD 
 (34.6 miles away)
410-955-8964
Languages Spoken:
English
See accepted insurances

Mario Eisenberger is an Oncologist in Baltimore, Maryland. Dr. Eisenberger is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Prostate Cancer, Chromophobe Renal Cell Carcinoma, Familial Prostate Cancer, Hormone Replacement Therapy (HRT), and Prostatectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Paller's expertise for a condition
ConditionClose
View All 18 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile